Conexeu Sciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.40next fiscal year
Monitoring Framework
Key Performance Indicators
FDA 510(k) Submission Progress QuarterlyTarget: Submission of premarket notification for initial wound care indication
Preclinical Evidence Base (P.R.O.O.F Study) Annually100.0Target: 100% completion of 12-month preclinical program and preparation for peer-reviewed publication
Watch Items
- FDA 510(k) Submission TimelineTrigger: Delay beyond Q1 2027Action: Re-evaluate clinical development timeline, cash runway, and commercialization strategy for the aesthetics market.
- Patent Assignment Agreement Final SettlementTrigger: Failure to fully settle remaining payments by November 20, 2027Action: Assess risk of losing core platform IP rights and coordinate emergency financing or renegotiation with the University.
Research as of 24 Jul 2026